Geron closed at $2.12 on Friday. The high for the week was $2.31 on Sept 30 and the low was $2.09 on Sept 26. The 50 day moving average is $2.49 which I think it will break in a few months. The new CEO John Scarlett brings on extensive track record of drug development and commercialization success. We will not have another secondary offering. Maybe when it hits $10.
Good luck in this rigged casino
I stopped buying stocks in 2014. Started trading options in June of 2014. Mostly IBB options. I'm using this blog for a record of my trades, good and bad, so I can look back and see if I can improve my trading. If you would like to trade along, don't, I some time hold options only for mins. A week or more I feel is a bad trade. Always remember it's a rigged casino
Friday, September 30, 2011
Thursday, September 29, 2011
Geron new CEO
John Scarlett is Geron's new CEO. He has 25 years of executive leadership. A Biotechnology Industry Veteran Brings Extensive Track Record of Drug Development and Commercialization Success.
Conference Call/Webcast Scheduled for 9:00 A.M. ET Tomorrow
This is great news there will be no more secondary stock of offerings. Maybe at $20+. Mr. Scarlett would not take the job unless he saw a great opportunity. Again I feel this is a great move by Geron.
Good luck in this rigged casino
Geron Longs will be rewarded
The true believers in the science, know in the not-too-distant future, the science will trump the market and all long-term investors will be handsomely rewarded. Keep the faith, buy the dips and sell the rips up. Trade around your core holdongs. I buy a few shares on the dips and when it goes up 20-30 cents I sell. Always remember you can lose all your money in any stock.
Good luck in this rigged casino
Good luck in this rigged casino
Wednesday, September 28, 2011
Geron the best
Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases. The company is advancing anti-cancer therapies through multiple Phase 2 clinical trials in different cancers by targeting the enzyme telomerase and with a conpound designed to penetrate the blood-brain barrier. The four Phase 2 trials end in Q4 of 2012 results shouuld be in Dec 2012. The company is developing cell therapies from differentiated human embryonic stem cells for a range of indications, with the first product in a Phase 1 clinical trial for spinal cord injury. Four patients are now in the trial. For more infor visit www.geron.com .
On this blog I will be stating news that may move the stock up or down. Will be stating my trades. Showing , hopefully how I make money while waiting for the big price move up to $100 a share. A dream, maybe. This stock could do it.
On this blog I will be stating news that may move the stock up or down. Will be stating my trades. Showing , hopefully how I make money while waiting for the big price move up to $100 a share. A dream, maybe. This stock could do it.
Subscribe to:
Posts (Atom)